Nature Reviews Cancer

, volume 21 , issue 8 , pages 481-499

Interleukins in cancer: from biology to therapy

Daria Briukhovetska ¹

Janina Dörr ¹

Stefan Endres ^{1, 2, 3}

Peter Libby ⁴

Charles A. Dinarello ⁵

Sebastian Kobold ^{1, 2, 3}

Hide authors affiliations Show authors affiliations: 5 affiliations

Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany |

German Center for Translational Cancer Research (DKTK), Munich, Germany |

Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany |

⁴

Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

Harvard University

Brigham and Women's Hospital

⁵

Department of Medicine, University of Colorado Denver, Aurora, USA |

Publication type: Journal Article

Publication date: 2021-06-03

Springer Nature

Nature Reviews Cancer

scimago Q1

wos Q1

SJR: 24.378

CiteScore: 103.8

Impact factor: 66.8

ISSN: 1474175X, 14741768

DOI: 10.1038/s41568-021-00363-z

Copy DOI

PubMed ID: 34083781

General Environmental Science

General Earth and Planetary Sciences

Abstract

Interleukins and associated cytokines serve as the means of communication for innate and adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a critical role in cancer development, progression and control. Interleukins can nurture an environment enabling and favouring cancer growth while simultaneously being essential for a productive tumour-directed immune response. These properties of interleukins can be exploited to improve immunotherapies to promote effectiveness as well as to limit side effects. This Review aims to unravel some of these complex interactions. This Review provides an update of interleukins in tumour biology, covering the milestones of the latest discoveries of interleukin-related mechanisms in cancer, together with their application in clinical practice. It includes an overview of current clinical trials and breakthrough preclinical concepts.

Found

1 citation

Abdalla Mohnad

🥼 🤝

DSc in Biological/biomedical sciences, associate professor

175 publications, 2 547 citations, 2 196 reviews

1 citation

Pintilie Lucia

61 publications, 500 citations, 12 reviews

1 citation

Bezborodova Olga

45 publications, 388 citations

h-index: 8

Herzen Moscow Oncology Research Institute

National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

MIREA — Russian Technological University

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Top-30

Journals

	5 10 15 20 25 30 35 40 45 50
Frontiers in Immunology	Frontiers in Immunology, 46, 7.62% Frontiers in Immunology 46 publications, 7.62%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 26, 4.3% International Journal of Molecular Sciences 26 publications, 4.3%
Cancers	Cancers, 21, 3.48% Cancers 21 publications, 3.48%
Frontiers in Oncology	Frontiers in Oncology, 15, 2.48% Frontiers in Oncology 15 publications, 2.48%
Biomedicines	Biomedicines, 9, 1.49% Biomedicines 9 publications, 1.49%
Scientific Reports	Scientific Reports, 8, 1.32% Scientific Reports 8 publications, 1.32%
International Immunopharmacology	International Immunopharmacology, 7, 1.16% International Immunopharmacology 7 publications, 1.16%
Cancer Letters	Cancer Letters, 7, 1.16% Cancer Letters 7 publications, 1.16%
Signal Transduction and Targeted Therapy	Signal Transduction and Targeted Therapy, 6, 0.99% Signal Transduction and Targeted Therapy 6 publications, 0.99%
Cytokine	Cytokine, 6, 0.99% Cytokine 6 publications, 0.99%
Journal for ImmunoTherapy of Cancer	Journal for ImmunoTherapy of Cancer, 6, 0.99% Journal for ImmunoTherapy of Cancer 6 publications, 0.99%
bioRxiv	bioRxiv, 6, 0.99% bioRxiv 6 publications, 0.99%
Cells	Cells, 5, 0.83% Cells 5 publications, 0.83%
Journal of Experimental and Clinical Cancer Research	Journal of Experimental and Clinical Cancer Research, 5, 0.83% Journal of Experimental and Clinical Cancer Research 5 publications, 0.83%
Molecular Cancer	Molecular Cancer, 4, 0.66% Molecular Cancer 4 publications, 0.66%
Journal of Translational Medicine	Journal of Translational Medicine, 4, 0.66% Journal of Translational Medicine 4 publications, 0.66%
Biomedicine and Pharmacotherapy	Biomedicine and Pharmacotherapy, 4, 0.66% Biomedicine and Pharmacotherapy 4 publications, 0.66%
Pathology Research and Practice	Pathology Research and Practice, 4, 0.66% Pathology Research and Practice 4 publications, 0.66%
Advanced Therapeutics	Advanced Therapeutics, 4, 0.66% Advanced Therapeutics 4 publications, 0.66%
eLife	eLife, 4, 0.66% eLife 4 publications, 0.66%
Advanced Science	Advanced Science, 4, 0.66% Advanced Science 4 publications, 0.66%
Journal of the American Chemical Society	Journal of the American Chemical Society, 4, 0.66% Journal of the American Chemical Society 4 publications, 0.66%
Nature Communications	Nature Communications, 3, 0.5% Nature Communications 3 publications, 0.5%
Genes	Genes, 3, 0.5% Genes 3 publications, 0.5%
Pharmaceuticals	Pharmaceuticals, 3, 0.5% Pharmaceuticals 3 publications, 0.5%
Frontiers in Pharmacology	Frontiers in Pharmacology, 3, 0.5% Frontiers in Pharmacology 3 publications, 0.5%
Cancer Immunology, Immunotherapy	Cancer Immunology, Immunotherapy, 3, 0.5% Cancer Immunology, Immunotherapy 3 publications, 0.5%
BMC Cancer	BMC Cancer, 3, 0.5% BMC Cancer 3 publications, 0.5%
Seminars in Cancer Biology	Seminars in Cancer Biology, 3, 0.5% Seminars in Cancer Biology 3 publications, 0.5%
	5 10 15 20 25 30 35 40 45 50

Publishers

	20 40 60 80 100 120 140
Elsevier	Elsevier, 137, 22.68% Elsevier 137 publications, 22.68%
Springer Nature	Springer Nature, 115, 19.04% Springer Nature 115 publications, 19.04%
MDPI	MDPI, 92, 15.23% MDPI 92 publications, 15.23%
Frontiers Media S.A.	Frontiers Media S.A., 73, 12.09% Frontiers Media S.A. 73 publications, 12.09%
Wiley	Wiley, 53, 8.77% Wiley 53 publications, 8.77%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 18, 2.98% Cold Spring Harbor Laboratory 18 publications, 2.98%
Taylor & Francis	Taylor & Francis, 15, 2.48% Taylor & Francis 15 publications, 2.48%
American Chemical Society (ACS)	American Chemical Society (ACS), 11, 1.82% American Chemical Society (ACS) 11 publications, 1.82%
BMJ	BMJ, 8, 1.32% BMJ 8 publications, 1.32%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 6, 0.99% Ovid Technologies (Wolters Kluwer Health) 6 publications, 0.99%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 6, 0.99% American Association for Cancer Research (AACR) 6 publications, 0.99%
Spandidos Publications	Spandidos Publications, 5, 0.83% Spandidos Publications 5 publications, 0.83%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 4, 0.66% American Association for the Advancement of Science (AAAS) 4 publications, 0.66%
eLife Sciences Publications	eLife Sciences Publications, 4, 0.66% eLife Sciences Publications 4 publications, 0.66%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 4, 0.66% Bentham Science Publishers Ltd. 4 publications, 0.66%
Research Square Platform LLC	Research Square Platform LLC, 4, 0.66% Research Square Platform LLC 4 publications, 0.66%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 3, 0.5% Royal Society of Chemistry (RSC) 3 publications, 0.5%
Hindawi Limited	Hindawi Limited, 2, 0.33% Hindawi Limited 2 publications, 0.33%
American Society for Clinical Investigation	American Society for Clinical Investigation, 2, 0.33% American Society for Clinical Investigation 2 publications, 0.33%
S. Karger AG	S. Karger AG, 2, 0.33% S. Karger AG 2 publications, 0.33%
SAGE	SAGE, 2, 0.33% SAGE 2 publications, 0.33%
Oxford University Press	Oxford University Press, 2, 0.33% Oxford University Press 2 publications, 0.33%
Baishideng Publishing Group	Baishideng Publishing Group, 2, 0.33% Baishideng Publishing Group 2 publications, 0.33%
AME Publishing Company	AME Publishing Company, 2, 0.33% AME Publishing Company 2 publications, 0.33%
F1000 Research	F1000 Research, 1, 0.17% F1000 Research 1 publication, 0.17%
PeerJ	PeerJ, 1, 0.17% PeerJ 1 publication, 0.17%
The Electrochemical Society	The Electrochemical Society, 1, 0.17% The Electrochemical Society 1 publication, 0.17%
American Society of Hematology	American Society of Hematology, 1, 0.17% American Society of Hematology 1 publication, 0.17%
LLC Global Media Technology	LLC Global Media Technology, 1, 0.17% LLC Global Media Technology 1 publication, 0.17%
	20 40 60 80 100 120 140

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

607

Cite this

GOST |

Cite this

GOST Copy

Briukhovetska D. et al. Interleukins in cancer: from biology to therapy // Nature Reviews Cancer. 2021. Vol. 21. No. 8. pp. 481-499.

GOST all authors (up to 50) Copy

Briukhovetska D., Dörr J., Endres S., Libby P., Dinarello C. A., Kobold S. Interleukins in cancer: from biology to therapy // Nature Reviews Cancer. 2021. Vol. 21. No. 8. pp. 481-499.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1038/s41568-021-00363-z

UR - https://doi.org/10.1038/s41568-021-00363-z

TI - Interleukins in cancer: from biology to therapy

T2 - Nature Reviews Cancer

AU - Briukhovetska, Daria

AU - Dörr, Janina

AU - Endres, Stefan

AU - Libby, Peter

AU - Dinarello, Charles A.

AU - Kobold, Sebastian

PY - 2021

DA - 2021/06/03

PB - Springer Nature

SP - 481-499

IS - 8

VL - 21

PMID - 34083781

SN - 1474-175X

SN - 1474-1768

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2021_Briukhovetska,

author = {Daria Briukhovetska and Janina Dörr and Stefan Endres and Peter Libby and Charles A. Dinarello and Sebastian Kobold},

title = {Interleukins in cancer: from biology to therapy},

journal = {Nature Reviews Cancer},

year = {2021},

volume = {21},

publisher = {Springer Nature},

month = {jun},

url = {https://doi.org/10.1038/s41568-021-00363-z},

number = {8},

pages = {481--499},

doi = {10.1038/s41568-021-00363-z}

}

MLA

Cite this

MLA Copy

Briukhovetska, Daria, et al. “Interleukins in cancer: from biology to therapy.” Nature Reviews Cancer, vol. 21, no. 8, Jun. 2021, pp. 481-499. https://doi.org/10.1038/s41568-021-00363-z.

Publisher

Springer Nature

Journal

Nature Reviews Cancer

scimago Q1

wos Q1

SJR

24.378

CiteScore

103.8

Impact factor

66.8

ISSN

1474175X (Print)

14741768 (Electronic)